Leitha T, Glaser C, Pruckmayer M, Rasse M, Millesi W, Lang S, Nasel C, Backfrieder W, Kainberger F
University Clinic of Nuclear Medicine, Department of Biomedical Engineering and Physics, Vienna, Austria.
J Nucl Med. 1998 Jul;39(7):1166-71.
We prospectively investigated 200 patients with the clinical suspicion for head and neck tumors. The final diagnoses were 94 primary and 56 (37 confirmed, 19 excluded) recurrent squamous cell carcinomas (SCCs), 3 primary and 7 (4 confirmed, 3 excluded) recurrent adenoid cystic carcinomas (ACCs), 6 non-Hodgkin's lymphomas, 10 distant metastases, 6 other malignancies, 10 inflammatory and 8 other nonmalignant conditions.
Bone (600 MBq 99mTc-3,3-diphosphono-1,2-propane dicarboxylic acid tetrasodium salt) and hexakis-2-methoxyisobutyl isonitrile (MIBI) (600 MBq 99mTc-MIBI) SPECT were both performed under identical conditions (triple-head gamma camera; ultra-high-resolution, parallel-hole collimators; three-dimensional postfiltering) and judged independently and after superimposition. The results were compared to the results of biopsy, surgery and CT.
The overall sensitivity/specificity of MIBI was 90%/78% for tumor detection and 90%/95% for the identification of malignant lymph node involvement (CT: 79%/66%, respectively 90%/79%). In the subgroup of recurrent SCC and ACC the sensitivity/specificity for tumor detection was 95%/71% for MIBI versus 78%/68% for CT. The isolated assessment of bone SPECT had a sensitivity/specificity of 100%/17% for osseous tumor spread. Image fusion of MIBI and bone SPECT differentiated between regio-local bone involvement and inflammatory changes and increased the specificity of bone SPECT to 100% in primary staging. Tumor size, stage, histology and pretreatment had no statistically significant effect on tracer uptake or diagnostic utility of scintigraphy.
We propose the combined 99mTc-MIBI and bone ultra-high resolution SPECT as a highly useful imaging approach in the primary and secondary staging in patients with suspected malignancies in the head and neck region. The high specificity for malignancies in the head and neck region may be used in the differential diagnosis between head and neck malignancies and inflammatory disease in patients with the accidental finding of enlarged lymph nodes and no clinical signs of a primary tumor. Image fusion with bone scanning is mandatory for the topographical orientation and increases the specificity of bone scanning to differentiate between inflammatory or malignant causes of increased bone metabolism.
我们前瞻性地研究了200例临床怀疑患有头颈部肿瘤的患者。最终诊断结果为94例原发性和56例(37例确诊,19例排除)复发性鳞状细胞癌(SCC),3例原发性和7例(4例确诊,3例排除)复发性腺样囊性癌(ACC),6例非霍奇金淋巴瘤,10例远处转移,6例其他恶性肿瘤,10例炎症性疾病和8例其他非恶性疾病。
在相同条件下(三头γ相机;超高分辨率、平行孔准直器;三维后置滤波)同时进行骨(600MBq 99mTc-3,3-二膦酰基-1,2-丙烷二羧酸四钠盐)和六甲基异丁基异腈(MIBI)(600MBq 99mTc-MIBI)单光子发射计算机断层显像(SPECT),并独立判断和叠加后判断。将结果与活检、手术及CT结果进行比较。
MIBI检测肿瘤的总体敏感性/特异性分别为90%/78%,识别恶性淋巴结受累的敏感性/特异性分别为90%/95%(CT分别为79%/66%和90%/79%)。在复发性SCC和ACC亚组中,MIBI检测肿瘤的敏感性/特异性为95%/71%,而CT为78%/68%。单独评估骨SPECT对骨肿瘤扩散的敏感性/特异性为100%/17%。MIBI和骨SPECT的图像融合可区分局部骨受累和炎症改变,并在初次分期中将骨SPECT的特异性提高到100%。肿瘤大小、分期、组织学和预处理对示踪剂摄取或闪烁显像的诊断效用无统计学显著影响。
我们建议将99mTc-MIBI和骨超高分辨率SPECT联合应用,作为头颈部可疑恶性肿瘤患者初次和二次分期中一种非常有用的成像方法。头颈部恶性肿瘤的高特异性可用于在偶然发现淋巴结肿大且无原发性肿瘤临床体征的患者中,对头颈部恶性肿瘤和炎症性疾病进行鉴别诊断。与骨扫描的图像融合对于定位至关重要,并可提高骨扫描区分骨代谢增加的炎症或恶性原因的特异性。